Skip to main content

Clinical Trials & Behavioral Studies

The Department of Psychiatry and Behavioral Sciences welcomes research participants ages 12 to 70 to enroll in studies aimed at improving the diagnosis and treatment of schizophrenia, bipolar disorder, Alzheimer’s disease, depression and anxiety. Browse the entries below and call the associated telephone numbers to learn how you can volunteer to help advance our understanding of psychiatric illness.

If you have questions, please call the Clinical Research Program office at 312-503-9100.

[search clinical trials]

Trials
Northwestern University Department of Psychiatry and Behavioral Sciences seeks to develop a research registry database compiled of individuals who are interested in participating in research studies. The database would utilize potential research participants who view the Department’s website. This…
Northwestern University Department of Psychiatry and Behavioral Sciences seeks to develop a research registry database compiled of individuals who are interested in participating in research studies. The database would utilize potential research participants who view the Department’s website. This application is not in itself a research project, but only for the establishment of the registry for recruitment. Recruitment will be for studies that have been approved by the Northwestern University Institutional Review Board. Advertising for the research database will be posted on the Department’s website. Our aim is to recruit psychiatric patients, their family members, and healthy controls for research on mood disorders, schizophrenia, and Alzheimer's disease.
Goldman, Morris BGoldman, Morris B
STU00034881
More Info
Copy
The recruitment pipeline provides research staff with an organized system of identifying researchsubjects.NU CRP clinical research studies covers a wide spectrum of Axis I Diagnoses such as schizophrenia, depression, anxiety, etc. NU CRP also conducts research studies for patients who are diagnosed …
The recruitment pipeline provides research staff with an organized system of identifying researchsubjects.NU CRP clinical research studies covers a wide spectrum of Axis I Diagnoses such as schizophrenia, depression, anxiety, etc. NU CRP also conducts research studies for patients who are diagnosed with certain neurological diseases such as Alzheimer’s disease, Tourette’s Syndrome, etc. NU CRP conducts basic, translational and clinical research. Personal Health Information (PHI) will not be collected. All information collected in this recruitmentregistry is based on the patient self-report. You will be contacted to answer additional questions by someone in the study staff and to determine your eligibility for the current studies.
Goldman, Morris BGoldman, Morris B
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
STU00059328
More Info
Copy
The primary goals of this study are to determine if rTMS is safe and tolerable in depressed cancer patients and to determine how well these two methods of rTMS work in treating cancer-related depression. You are being asked to take part in this study because you are a cancer patient in remission who…
The primary goals of this study are to determine if rTMS is safe and tolerable in depressed cancer patients and to determine how well these two methods of rTMS work in treating cancer-related depression. You are being asked to take part in this study because you are a cancer patient in remission who is depressed currently. In the future, we hope to be able to use rTMS on depressed cancer patients who are actively receiving cancer treatment. However, since this is a preliminary study, we will only include patients in remission. Finally, anxiety often accompanies depression. So, we are also interested in understanding your current level of anxiety and how rTMS affects any anxiety that you might have. Your participation in this study will last for approximately seven weeks and will involve 31 visits.
Dokucu, Mehmet EDokucu, Mehmet E
NCT01701284 STU00063218
More Info
Copy
Patients between 18 and 26 who arrive seeing treatment for new-onset mental health symptoms. They will receive treatment as usual, while being assessed overt he course of one year for changes in role functioning. During this study the investigators will 1) collect measures of social cognition and so…
Patients between 18 and 26 who arrive seeing treatment for new-onset mental health symptoms. They will receive treatment as usual, while being assessed overt he course of one year for changes in role functioning. During this study the investigators will 1) collect measures of social cognition and social functioning in adolescents and young adults who are experiencing early symptoms of a major mental disorder; and 2) evaluate the predictive value and utility of a new role functioning assessment measure for individuals experiencing changes in their lives after an index episode of mental illness. The primary outcome of the study is to correlate Role Functioning Rating Scale (RFRS), clinical symptoms, and social cognition. The early symptoms of major mental disorders, such as bipolar disorder and schizophrenia, can be non-specific, attenuated, or intermittent. These symptoms nevertheless frequently interfere with an individuals' ability to effectively carry-out multiple aspects of their everyday lives, including social, vocational, and educational functioning. Functional changes may in fact occur before individual symptoms reach the threshold for clinical significance. Relying solely on the emergence of early symptoms of psychopathology can delay treatment or lead to the improper selection of treatments that are not effective. Therefore, measuring changes in real-world functioning that correlate with or predate symptoms may be a useful tool for developing an effective treatment plan. While psychopharmacology and psychotherapy can improve some symptoms of severe mental illness, much less is known about the mechanisms for improving impairments in social cognition. Importantly social cognition affects not just social functioning, but many critical aspects of real-world functioning. Thus, advancing our understanding of how social cognition and real-world functioning change over time, and their association to changing clinical symptoms, will help improve our understanding of early mental illness, and should inform patient care in new ways. Currently, there are only a limited number of tools available for assessing aspects of real-world functioning as they connect to social cognition. Therefore, the overarching goal of the present study is to conduct a pilot study to develop a new tool that measures functioning and evaluate the relationship between this new tool and measures of social cognition and symptoms.
Inclusion Criteria:

Age 18 to 26 years
Individuals seeking treatment for psychiatric symptoms in a clinical care setting
Able to provide informed consent (age 18-26)
Subjects must consent to a review of the medical records in order to track changes in clinical symptoms
Fluent in English
Exclusion Criteria:

Adults unable to consent
Individuals who have not reached the age of 18
Pregnant women
Prisoners.
Cronenwett, Will JCronenwett, Will J
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
STU00201133
More Info
Copy
This study is being done to evaluate the use of a mobile phone intervention for bipolar disorder that aims to improve patient self-management and increase the effectiveness of psychological interventions. The goal is to reduce symptoms and prevent relapse in people with bipolar disorder. If you are …
This study is being done to evaluate the use of a mobile phone intervention for bipolar disorder that aims to improve patient self-management and increase the effectiveness of psychological interventions. The goal is to reduce symptoms and prevent relapse in people with bipolar disorder. If you are eligible for the study, your participation will last up to 12 months.
Individuals 18-65 years old who have been diagnosed with bipolar disorder and are currently working with a psychiatrist
Goulding, Evan HGoulding, Evan H
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
NCT03088462 STU00202860
More Info
Copy
This is a study ( http://enlightenstudy.com/ ) to evaluate the effect of the investigational drug compared to Olanzapine on body Weight in young adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder who are Early in their Illness. Participation will last up to 20 weeks. Before start…
This is a study ( http://enlightenstudy.com/ ) to evaluate the effect of the investigational drug compared to Olanzapine on body Weight in young adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder who are Early in their Illness. Participation will last up to 20 weeks. Before starting the study, each participant will be evaluated to determine his or her eligibility to participate. Each participant who qualifies will receive study-related tests, investigational medication and study-related care at no cost. Qualifying participants may be compensated for time and travel. If eligible, they will start the 12 week program where they are randomly assigned (like flipping a coin) to take one of two treatments. No one will know which type of treatment they are taking. During the 12 weeks, qualified participants will return for clinic visits where they will meet with the study doctor or staff and complete the following procedures: Interviews about symptoms, medical and psychiatric history, and general quality of life.Answer questions about the treatments they receive and how they are doing Measure their weight, blood pressure,

Ages Eligible for Study: 18 Years to 40 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria:
Has less than 10 weeks previous treatment with antipsychotics (cumulative; lifetime)
Has less than 4 years elapse since the initial onset of active-phase of symptoms
Have a body mass index (BMI) of 18.0 to <27.0 kg/m^2
Agrees to use an acceptable method of contraception for the duration of the study
Subject meets the criteria for a primary diagnosis of schizophrenia, schizophreniform disorder, or bipolar I disorder
For bipolar I disorder, must be currently experiencing an episode of acute mania
Suitable for outpatient treatment
Additional criteria may apply
Exclusion Criteria:
Poses a current suicide risk
Has a history of poor or inadequate response to treatment with olanzapine
Has previously been treated with long-acting injectable antipsychotic medication or has received treatment with electroconvulsive therapy in their lifetime
Currently treated with mood stabilizers (eg lithium, valproate)
Has a positive drug screen for opioids, phencyclidine (PCP), amphetamine/methamphetamine, or cocaine
Has taken opioid agonists (eg, codeine, oxycodone, tramadol, morphine) within the 14 days prior to Visit 1, or has taken opioid antagonists, including naltrexone and naloxone, within 60 days prior to Visit 1
Taking any weight loss agents or hypoglycemic agents
Has a clinically significant or unstable medical illness, condition, or disorder that would be anticipated to potentially compromise subject safety or adversely affect the evaluation of efficacy
Has joined a weight management program or had significant changes in diet or exercise regimen within the past 6 weeks
Has started a smoking cessation program within the past 6 months
Has a history of diabetes
Currently pregnant or breastfeeding or is planning to become pregnant during the study or within 30 days of the last study drug administration
Additional criteria may apply
Rado, Jeffrey ThomasRado, Jeffrey Thomas
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
NCT03187769 STU00205116
More Info
Copy
We are asking you to take part in this research study because you have major depressive disorder and you have tried an antidepressant in the past that has not helped your depression. Also, you have not had a satisfactory response from your current antidepressant medication. We expect that you will …
We are asking you to take part in this research study because you have major depressive disorder and you have tried an antidepressant in the past that has not helped your depression. Also, you have not had a satisfactory response from your current antidepressant medication. We expect that you will be in this research study for up to 12 weeks and we will ask you to make 7 study visits to Northwestern University.  
1. women and men ages 18-80,with major depressive disorder2. You have tried an antidepressant but less than 50% of the symptoms have resolved 
Dokucu, Mehmet EDokucu, Mehmet E
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
NCT02977299 STU00207732
More Info
Copy
The purpose of this study is to find out what effects, good or bad, the study medication RO6889450, has on you and symptoms of your schizophrenia or schizoaffective disorder. You were selected as a possible participant in this study because you have been diagnosed with schizophrenia or schizoaffect…
The purpose of this study is to find out what effects, good or bad, the study medication RO6889450, has on you and symptoms of your schizophrenia or schizoaffective disorder. You were selected as a possible participant in this study because you have been diagnosed with schizophrenia or schizoaffective disorder and negative symptoms (thoughts, feelings, or behaviors normally present that are absent or diminished in people with schizophrenia or schizoaffective disorder) This study is intended to contribute to the further development of the study medication. The study medication is still being tested and has not been approved by any national health authority, including the US Food and Drug Administration (FDA).
You have been diagnosed with schizophrenia or schizoaffective disorder and negative symptoms(thoughts, feelings, or behaviors normally present that are absent or diminished in people with schizophrenia or schizoaffective disorder) 
Rado, Jeffrey ThomasRado, Jeffrey Thomas
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
NCT03108846 STU00209192
More Info
Copy
This is a study to look at how safe and effective the study drug is in people with CognitiveImpairment Associated with Schizophrenia (CIAS). CIAS refers to some issues that people withschizophrenia may have, including having trouble remembering things, learning new things, ormaking good decisions.
We are asking you to take part in this research study because you have schizophrenia and may be having trouble remembering things, learning new things, or making good decisions.
Rado, Jeffrey ThomasRado, Jeffrey Thomas
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
NCT03745820 STU00210796
More Info
Copy
Earn $25/hour for completing the following components:1 screening visit (about 4 hours)2 study visits (about 8 hours each)1 phone call (about 10 minutes)You can get paid approximately $400-$500 for completing this study, and you will be reimbursed for parking or public transportation costs. For mor…
Earn $25/hour for completing the following components:1 screening visit (about 4 hours)2 study visits (about 8 hours each)1 phone call (about 10 minutes)You can get paid approximately $400-$500 for completing this study, and you will be reimbursed for parking or public transportation costs. For more information, please call the research coordinator at 312-503-5235 or email samuel.yoo@northwestern.edu.Investigator: James Reilly, PhDNU IRB: STU00211277Study Title: A Single-Dose Study Using Functional Magnetic Resonance Imaging to Evaluate the Effect of LY3154207 in Healthy Subjects
18-40 years oldIf female, need to be using a contraceptiveHave no history of psychiatric disorder or serious medical illness
Reilly, James LReilly, James L
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
NCT04258826 STU00211277
More Info
Copy
STOP COVID Trial is a randomized controlled trial that aims to help slow the progression of COVID-19 symptoms in symptomatic patients in the United States. The study is contactless meaning volunteers may participate without leaving their home. Medication and study supplies are delivered by a couri…
STOP COVID Trial is a randomized controlled trial that aims to help slow the progression of COVID-19 symptoms in symptomatic patients in the United States. The study is contactless meaning volunteers may participate without leaving their home. Medication and study supplies are delivered by a courier or shipped overnight. We hope our study will demonstrate whether or not taking a medication, fluvoxamine, will help to prevent worsening of symptoms and prevent hospitalization.
You may be eligible if you:Are age 30 or olderTested positive for COVID-19Are experiencing symptoms of COVID-19Have current symptoms of COVID-19 that started within the past 6 days.Have at least one of the following risk factors for developing serious COVID-19: age 40 or older, African-American, Hispanic/Latino, Native American, obesity, hypertension, or immune diseaseHave not been vaccinated against COVID-19You may be ineligible if you:Are experiencing severe symptoms that require hospitalizationAre unable to take the study medication, fluvoxamineAre taking one or more of the following medications: sertraline, donepezil, coumadin (warfarin), plavix (clopidogrel)
Rado, Jeffrey ThomasRado, Jeffrey Thomas
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
NCT04668950 STU00213714
More Info
Copy

Follow Psychiatry on